EPA Capsule Shell Oxidation Resistance via Antioxidant Parameters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
High purity eicosapentaenoic acid (EPA) is susceptible to oxidative degradation, and existing capsule shells, such as type IIa gelatin capsules, do not effectively prevent oxidation, which affects the stability and shelf life of mixed omega-3 fatty acid esters.
Innovation Solution
A pharmaceutical composition comprising ultra-pure EPA encapsulated in a capsule shell with a film-forming material and a hygroscopic plasticizer, where the weight ratio of film-forming material to hygroscopic plasticizer is not less than 2.5:1, and optionally including a non-hygroscopic plasticizer, to resist oxidation and maintain stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high purity EPA is encapsulated in standard type IIa gelatin capsules, then the capsule provides basic protection and is chemically stable, but the EPA undergoes oxidative degradation and loses stability
Solution Approach 1:
The patent changes the compositional parameters of the capsule shell by incorporating specific antioxidants (vitamin E, vitamin C, BHA, BHT) at defined concentrations (0.1-5% by weight of fill material) and adjusting the gelatin composition (type I or II gelatin with specific isoelectric points). These parameter changes transform the capsule from a passive container to an active protective system that chemically inhibits oxidation through radical scavenging mechanisms, thereby resolving the contradiction between basic capsule stability and EPA oxidative stability
Solution Approach 2:
The patent introduces antioxidant substances as intermediary agents between the EPA and oxygen. These antioxidants (vitamin E, vitamin C, BHA, BHT) act as mediators that preferentially react with free radicals and peroxides, preventing direct oxidation of EPA. The antioxidants serve as sacrificial intermediaries that protect the primary active ingredient through chemical intervention, resolving the stability contradiction
2Stability of the object's composition
If chemically modified gelatin (succinated/succinylated) is used to encapsulate reactive fill ingredients, then encapsulation stability is improved, but the gelatin is not approved for use in the U.S. and other markets
Solution Approach 1:
The patent changes the chemical composition parameters of the capsule shell by incorporating specific approved substances (gelatin types I or II with defined isoelectric points, glycerin, sorbitol, and approved antioxidants) at precise concentrations. This parameter optimization achieves encapsulation stability equivalent to or better than chemically modified gelatin while maintaining compliance with FDA and international regulatory requirements, thereby resolving the contradiction between stability and market approval
Solution Approach 2:
The patent uses antioxidants with shorter functional lifetimes (sacrificial antioxidants like vitamin C and BHA that deplete over time) to protect the EPA during storage. These short-lived protective agents are replenished through proper formulation, allowing the use of simple, approved gelatin materials instead of complex chemically modified gelatin, thus achieving both stability and regulatory compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents oxidation of EPA, maintaining its purity and stability during storage, with a baseline peroxide value not exceeding 5 meq/mg and a second peroxide value not greater than 20 meq/mg after storage, thereby extending the shelf life and ensuring bioavailability.
Implementation Method 1
a capsule shell that resists, hinders, attenuates, or prevents oxidation of the fatty acid or fatty acid derivative
Data Source
AI summary
The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.